- Press releasesPress releases
- Events & ActivityEvents & Activity
- Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium(TM) 2017
- Abeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium(TM) 2017
- Abeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A
- Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B
Abeona Therapeutics Inc (ABEO:NAQ) closed at 6.00, -36.44% below its 52-week high of 9.44, set on Oct 20, 2016.
2.05Mar 01 20169.44Oct 20 2016
Markit short selling activity
|Market cap||239.76m USD|
|EPS (TTM)||-0.524 USD|
Data delayed at least 15 minutes, as of Feb 17 2017 21:00 GMT.